NO20042768L - IFNAR2 mutanter, deres fremstilling og anvendelse - Google Patents

IFNAR2 mutanter, deres fremstilling og anvendelse

Info

Publication number
NO20042768L
NO20042768L NO20042768A NO20042768A NO20042768L NO 20042768 L NO20042768 L NO 20042768L NO 20042768 A NO20042768 A NO 20042768A NO 20042768 A NO20042768 A NO 20042768A NO 20042768 L NO20042768 L NO 20042768L
Authority
NO
Norway
Prior art keywords
preparation
ifnar2
mutants
ifnar2 mutants
Prior art date
Application number
NO20042768A
Other languages
English (en)
Other versions
NO333821B1 (no
Inventor
Giedon Schreiber
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20042768L publication Critical patent/NO20042768L/no
Publication of NO333821B1 publication Critical patent/NO333821B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
NO20042768A 2001-12-31 2004-06-30 IFNAR2 mutantpolypeptid, anvendelse derav, samt farmasøytisk preparat omfattende nevnte mutantpolypeptid NO333821B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14741401A IL147414A0 (en) 2001-12-31 2001-12-31 Ifnar2 mutants, their production and use
PCT/IL2002/001059 WO2003059950A1 (en) 2001-12-31 2002-12-31 Ifnar2 mutants, their production and use

Publications (2)

Publication Number Publication Date
NO20042768L true NO20042768L (no) 2004-09-22
NO333821B1 NO333821B1 (no) 2013-09-23

Family

ID=11075916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042768A NO333821B1 (no) 2001-12-31 2004-06-30 IFNAR2 mutantpolypeptid, anvendelse derav, samt farmasøytisk preparat omfattende nevnte mutantpolypeptid

Country Status (16)

Country Link
US (2) US7749735B2 (no)
EP (2) EP1461358A1 (no)
JP (2) JP2005527195A (no)
KR (1) KR100891918B1 (no)
CN (1) CN100506845C (no)
BR (1) BR0215414A (no)
CA (1) CA2470245C (no)
EA (1) EA009604B1 (no)
HK (1) HK1072948A1 (no)
IL (2) IL147414A0 (no)
MX (1) MXPA04006383A (no)
NO (1) NO333821B1 (no)
NZ (1) NZ533539A (no)
UA (1) UA87958C2 (no)
WO (1) WO2003059950A1 (no)
ZA (1) ZA200404731B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
CN103952413B (zh) * 2014-05-14 2016-08-17 广东省农业科学院动物卫生研究所 靶向ifnar2基因的rna干扰表达载体构建及应用
CN104762325B (zh) * 2015-03-30 2018-04-17 山东省农业科学院家禽研究所 一种沉默df‑1细胞系中ifnar2基因的方法
CN105396123A (zh) * 2015-11-20 2016-03-16 深圳市南山区人民医院 ovR2E蛋白在HBV感染治疗中疗效的应用
EP4410378A3 (en) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
CA1341369C (en) 1985-10-14 2002-06-18 Michel Revel Human interferon-.beta.2a and interferon-.beta.2b; vectors containing genes coding for said interferons: cell lines producing same and use of said interferons as pharmaceuticals
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
HUP9900619A3 (en) * 1996-02-20 2001-11-28 Applied Research Systems Hybrid proteins which form heterodimers
DK1037658T3 (da) 1997-12-19 2002-09-30 Applied Research Systems IFNAR2/IFN-kompleks
IL126562A0 (en) 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation

Also Published As

Publication number Publication date
CA2470245A1 (en) 2003-07-24
EP1461358A1 (en) 2004-09-29
EP2174955A1 (en) 2010-04-14
UA87958C2 (ru) 2009-09-10
IL162507A (en) 2011-01-31
NO333821B1 (no) 2013-09-23
US20050164185A1 (en) 2005-07-28
CN100506845C (zh) 2009-07-01
AU2002366976A1 (en) 2003-07-30
KR20040086255A (ko) 2004-10-08
JP2009165483A (ja) 2009-07-30
CN1622957A (zh) 2005-06-01
EP2174955B1 (en) 2014-04-16
US20100239530A1 (en) 2010-09-23
EA009604B1 (ru) 2008-02-28
HK1072948A1 (en) 2005-09-16
JP2005527195A (ja) 2005-09-15
WO2003059950A1 (en) 2003-07-24
KR100891918B1 (ko) 2009-04-08
CA2470245C (en) 2012-03-27
EA200400894A1 (ru) 2004-12-30
NZ533539A (en) 2008-05-30
ZA200404731B (en) 2005-08-31
IL147414A0 (en) 2002-08-14
MXPA04006383A (es) 2004-10-04
US7749735B2 (en) 2010-07-06
BR0215414A (pt) 2004-12-14

Similar Documents

Publication Publication Date Title
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO20015156L (no) 5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
IL159015A0 (en) Polypeptides, their preparation and use
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20034159D0 (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
NO20031838D0 (no) Benzokazinonderivater, deres fremstilling og anvendelse
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
IL158397A0 (en) Polypeptides, their preparation and their use
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
HK1072948A1 (en) Ifnar2 mutants, their production and use
DK1353912T3 (da) 2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse
NO20023144D0 (no) Kompleks omfattende OCIF og polysakkarid
NO20025209L (no) Cyklipostiner, deres fremstilling og anvendelse
NO20024107L (no) Tienopyridin derivater, deres fremstilling og anvendelse
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
DK1010689T3 (da) Substituerede cycloheptener, deres fremstilling og anvendelse
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
NO20001782D0 (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees